Ertugliflozin
Summary
Ertugliflozin is a SGLT2 inhibitor used to treat type 2 diabetes mellitus.
Background
Ertugliflozin belongs to the class of potent and selective inhibitors of the sodium-dependent glucose cotransporters (SGLT), more specifically the type 2 which is responsible for about 90% of the glucose reabsorption from glomerulus.1 This drug was developed under the collaboration of Merck and Pfizer. It was FDA approved as monotherapy and in combination with sitagliptin or metformin hydrochloride on December 22, 2017.6
Weight Average: 436.89
Monoisotopic: 436.1288808
Chemical Formula: C22H25ClO7